Its inhibition enhances insulin signaling and attenuates insulin resistance both in conventional and non conventional insulin-responsive tissues [21], indicating PTP1B as a target for the development of novel therapeutics for diabetes and obesity. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.